Details of the Drug Combinations

General Information of This Drug (ID: DMRL3AB)

• Drug Name: Famotidine (DMRL3AB)
• Synonyms: Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide

Indication

Gastric ulcer; ICD 11: DA60; Status: Approved [1]; Gastrinoma; ICD 11: 2C10.1; Status: Approved [1]; Peptic esophagitis; ICD 11: N.A.; Status: Approved [1]; Peptic ulcer; ICD 11: DA61; Status: Approved [2]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 3 [3]

• Therapeutic Class: Antiulcer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Famotidine + Idarubicin	DCRRHA3	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]

11 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acetylcysteine + Famotidine	DCFGZ9K	Acetylcysteine	Covid19	[5]
CB-839 + Famotidine	DCAKWHT	CB-839	Drug Interaction	[6]
Famotidine + Raltegravir	DCGL2JR	Raltegravir	HIV-1 Infection	[7]
Savolitinib + Famotidine	DCOD3O8	Savolitinib	Solid Tumours	[8]
Telotristat ethyl + Famotidine	DCJK72Y	Telotristat ethyl	Drug-drug Interaction	[9]
Acetazolamide + Famotidine	DCO6YIA	Acetazolamide	Acute Cerebrovascular Accident	[10]
Celecoxib + Famotidine	DC7T9H6	Celecoxib	2019 Novel Coronavirus Disease	[11]
Diphenhydramine + Famotidine	DCL5NQ1	Diphenhydramine	Acute Cerebrovascular Accident	[10]
Loratadine + Famotidine	DCRECFY	Loratadine	Eosinophilic Esophagitis	[12]
Cetirizine + Famotidine	DCROKV5	Cetirizine	COVID-19	[13]
R0-93877 + Famotidine	DC53782	R0-93877	Esophageal Motility Disorders	[14]

References

• [1] Famotidine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7074).
• [3] ClinicalTrials.gov (NCT04370262) Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19. U.S. National Institutes of Health.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] ClinicalTrials.gov (NCT04545008) Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
• [6] ClinicalTrials.gov (NCT04540965) Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
• [7] ClinicalTrials.gov (NCT01000818) A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
• [8] ClinicalTrials.gov (NCT04179071) A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
• [9] ClinicalTrials.gov (NCT03302845) A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
• [10] ClinicalTrials.gov (NCT02142712) Histamine Glutamate Antagonism in Stroke
• [11] ClinicalTrials.gov (NCT05077332) LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
• [12] ClinicalTrials.gov (NCT04248712) Antihistamines in Eosinophilic Esophagitis
• [13] ClinicalTrials.gov (NCT05946551) Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
• [14] ClinicalTrials.gov (NCT05455359) Gastrointestinal Dysmotility on Aspiration Risk